# Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial

> **NCT00643968** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 140 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** EFV+TDF
- **DRUG:** EFV+3TC+TDF

## Key facts

- **NCT ID:** NCT00643968
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2005-06
- **Final completion:** 2005-09
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2008-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00643968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00643968, "Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00643968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*